Gilead Sciences | Umsatzkosten

Aktienkurs
151.12
Täglich Wechseln
-1.62 -1.06%
Monatlich
21.73%
Jährlich
37.34%
Q1 Prognose
150.18




Umsatzkosten Veränderung Datum
AbbVie USD 4.55B 757M 2025-12
Agios Pharmaceuticals USD 1.88M 199K 2025-12
ALKERMES USD 51.59M 2.13M 2025-09
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 144.93M 10M 2025-09
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Coherus Biosciences USD 2.65M 31.2M 2025-03
Eli Lilly USD 3.37B 363.7M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Glaxosmithkline GBP 3.01B 853.01M 2025-09
Incyte USD 121.18M 22.18M 2025-12
J&J USD 7.97B 689M 2025-12
Merck USD 3.32B 531M 2025-12
Moderna USD 452M 245M 2025-12
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 217M 2025-09
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 23.32M 7.83M 2025-09
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 4.29B 421M 2025-12
Sarepta Therapeutics USD 151.45M 1.77M 2025-09
United Therapeutics USD 100.9M 74.3M 2025-09
Vertex Pharmaceuticals USD 466M 51.2M 2025-12


Gilead Sciences Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.